Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies - PubMed (original) (raw)
Comparative Study
. 2001 Jun 15;10(13):1413-9.
doi: 10.1093/hmg/10.13.1413.
L J Rush, M C Frühwald, Z Dai, W A Held, J F Costello, J C Lang, C Eng, B Li, F A Wright, M A Caligiuri, C Plass
Affiliations
- PMID: 11440994
- DOI: 10.1093/hmg/10.13.1413
Comparative Study
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies
D J Smiraglia et al. Hum Mol Genet. 2001.
Abstract
Cancer cell lines are widely used in many types of cancer research, including studies aimed at understanding DNA hypermethylation of gene promoters in cancer. Hypermethylation of promoters is capable of repressing the expression of tumor suppressor genes and may play a role in the development and/or progression of cancer. Although both primary malignancies and cancer cell lines exhibit this epigenetic phenomenon, there has been no direct comparison between them. In order to address this question, we have utilized restriction landmark genomic scanning to measure the hypermethylation phenotypes of cancer cell lines and compared these data with the same analysis performed on primary malignancies. In all cases, cancer cell lines exhibit significantly higher levels of CpG island hypermethylation than the primary malignancies they represent. Colon cancer cell lines are most similar to their respective tumors, with only a 5-fold increase in hypermethylation, while head and neck squamous cell carcinoma cell lines show a 93-fold increase in hypermethylation. Furthermore, >57% of the loci methylated in cell lines are never methylated in 114 primary malignancies studied. Seventy percent of loci hypermethylated in cell lines are hypermethylated in lines from more than one type of cancer. These data indicate that most CpG island hypermethylation observed in cancer cell lines is due to an intrinsic property of cell lines as opposed to the malignant tissue from which they originated.
Similar articles
- Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y. Yuan J, et al. Cancer Res. 2003 Jul 15;63(14):4174-80. Cancer Res. 2003. PMID: 12874023 - Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
Zhong S, Tang MW, Yeo W, Liu C, Lo YM, Johnson PJ. Zhong S, et al. Clin Cancer Res. 2002 Apr;8(4):1087-92. Clin Cancer Res. 2002. PMID: 11948118 - Predicting aberrant CpG island methylation.
Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Feltus FA, et al. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12253-8. doi: 10.1073/pnas.2037852100. Epub 2003 Sep 30. Proc Natl Acad Sci U S A. 2003. PMID: 14519846 Free PMC article. - The study of aberrant methylation in cancer via restriction landmark genomic scanning.
Smiraglia DJ, Plass C. Smiraglia DJ, et al. Oncogene. 2002 Aug 12;21(35):5414-26. doi: 10.1038/sj.onc.1205608. Oncogene. 2002. PMID: 12154404 Review. - CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M. Esteller M. Oncogene. 2002 Aug 12;21(35):5427-40. doi: 10.1038/sj.onc.1205600. Oncogene. 2002. PMID: 12154405 Review.
Cited by
- DNA Methylation as Drug Sensitivity Marker in RCC: A Systematic Review.
Koudonas A, Dimitriadis G, Anastasiadis A, Papaioannou M. Koudonas A, et al. Epigenomes. 2024 Jul 15;8(3):28. doi: 10.3390/epigenomes8030028. Epigenomes. 2024. PMID: 39051186 Free PMC article. Review. - MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.
Pickles OJ, Wanigasooriya K, Ptasinska A, Patel AJ, Robbins HL, Bryer C, Whalley CM, Tee L, Lal N, Pinna CMA, Elzefzafy N, Taniere P, Beggs AD, Middleton GM. Pickles OJ, et al. Cancer Res Commun. 2023 Aug 9;3(8):1501-1513. doi: 10.1158/2767-9764.CRC-23-0091. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37565053 Free PMC article. - Dynamic antagonism between key repressive pathways maintains the placental epigenome.
Weigert R, Hetzel S, Bailly N, Haggerty C, Ilik IA, Yung PYK, Navarro C, Bolondi A, Kumar AS, Anania C, Brändl B, Meierhofer D, Lupiáñez DG, Müller FJ, Aktas T, Elsässer SJ, Kretzmer H, Smith ZD, Meissner A. Weigert R, et al. Nat Cell Biol. 2023 Apr;25(4):579-591. doi: 10.1038/s41556-023-01114-y. Epub 2023 Apr 6. Nat Cell Biol. 2023. PMID: 37024684 Free PMC article. - CDH1 (E-cadherin) Gene Methylation in Human Breast Cancer: Critical Appraisal of a Long and Twisted Story.
Bücker L, Lehmann U. Bücker L, et al. Cancers (Basel). 2022 Sep 8;14(18):4377. doi: 10.3390/cancers14184377. Cancers (Basel). 2022. PMID: 36139537 Free PMC article. Review. - Computational estimation of quality and clinical relevance of cancer cell lines.
Trastulla L, Noorbakhsh J, Vazquez F, McFarland J, Iorio F. Trastulla L, et al. Mol Syst Biol. 2022 Jul;18(7):e11017. doi: 10.15252/msb.202211017. Mol Syst Biol. 2022. PMID: 35822563 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- CA80912/CA/NCI NIH HHS/United States
- DE13123/DE/NIDCR NIH HHS/United States
- GM58934/GM/NIGMS NIH HHS/United States
- P30 CA16058/CA/NCI NIH HHS/United States
- T32 CA09338-20/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources